Application of fatty acid amide hydrolase inhibitor PF-3845 in preparation of medicine for treating alveolar echinococcosis
By using the fatty acid amide hydrolase inhibitor PF-3845, the structure of Echinococcus multi-apartment is destroyed, and the problem of poor efficacy of existing vesicular hydococcus is solved, and effective treatment of vesicular hydococcus is achieved.
Patent Information
- Application Number
- CN202411421957.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-12
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2044-10-12
AI Technical Summary
Existing therapeutic drugs for vesicular hydatosis such as albendazole have low absorption rate and obvious side effects in the liver, resulting in poor efficacy, and it is urgent to develop new effective therapeutic drugs.
Using the fatty acid amide hydrolase inhibitor PF-3845, the activity of FAAH is inhibited by carbamate reaction with the serine nucleophilic reagent of FAAH, thereby destroying the structure of Echinococcus multi-academic ceramide and causing its death.
PF-3845 significantly reduces the activity of Echinococcus multi-apartment and the integrity of vesicles during the tape stage, has a good killing effect, and can be used as a therapeutic drug for vesicular hydatosis.
Smart Images

Figure FT_1 
Figure FT_2 
Figure FT_3
Abstract
Description
Technical Field
[0001] The invention relates to the application of fatty acid amide hydrolase inhibitor PF-3845 in the preparation of medicine for treating alveolar echinococcosis in the field of biomedicine. Background Art
[0002] Alveolar echinococcosis (AE) is caused by Echinococcus multilocularis ( Echinococcus multilocularis , E.m ) larvae (alveolar cysts) parasitize the human liver and cause a fatal parasitic disease. The clinical manifestations of the disease are similar to liver cancer, commonly known as "worm cancer". AE seriously threatens people's health and life safety, has become a serious public health problem, and is one of the "new five major parasitic diseases" that are focused on prevention and treatment. At present, the clinical treatment of AE patients is mainly based on surgical resection of lesions, while for AE patients who cannot undergo surgery or to prevent recurrence after surgery, drug treatment has become the first choice. The first choice drug recommended by WHO for the treatment of echinococcosis is albendazole (ABZ), but ABZ has a low intestinal absorption rate and must be converted into albendazole sulfoxide in the liver to work. Albendazole sulfoxide mainly kills the worm by interfering with the energy metabolism of the worm and affecting the structure and function of the worm's microtubule protein. The side effects on the liver are more obvious, resulting in low bioavailability of ABZ and poor efficacy. Therefore, there is an urgent need to develop effective drugs for the treatment of AE. In recent years, the research and development of drugs for the treatment of alveolar echinococcosis has mainly been studied and applied from the aspects of discovering new drugs.
[0003] Fatty acid amide hydrolase (FAAH) FAAH belongs to the serine hydrolase family and is one of the main hydrolases of endogenous cannabinoids. It is widely present in the nervous system and can affect cell proliferation, apoptosis and differentiation by regulating the degradation of N-arachidonic acid ethanolamine. It is involved in regulating the body's pain and appetite, regulating neurotransmitter release and inflammatory response and other physiological functions. Studies have reported that the use of FAAH inhibitors can indirectly increase the level of N-arachidonic acid ethanolamine in the body and exert anti-tumor effects by inducing apoptosis, inhibiting tumor cell migration and angiogenesis.
[0004] PF-3845 is a highly effective, selective, irreversible and orally available FAAH inhibitor that covalently inhibits the activity of FAAH by reacting with the serine nucleophile of FAAH to undergo carbamate reaction. In in vivo studies, the use of FAAH inhibitor PF-3845 has been shown to significantly reduce pain, inflammation and anti-tumor effects in a variety of diseases. However, there has been no report on the use of FAAH inhibitor PF-3845 for the treatment of alveolar echinococcosis. Summary of the invention
[0005] The technical problem to be solved by the present invention is how to treat and / or prevent alveolar echinococcosis.
[0006] In order to solve the above technical problems, the present invention first provides any of the following applications: 1. Use of a substance that inhibits the expression of the FAAH gene in the preparation of a product for treating and / or preventing alveolar echinococcosis, or in the treatment of alveolar echinococcosis; 2. Use of substances that reduce the content or activity of FAAH in the preparation of products for treating alveolar echinococcosis, or in the treatment of alveolar echinococcosis; 3. Use of FAAH inhibitors in the preparation of products for treating alveolar echinococcosis, or in the treatment of alveolar echinococcosis; 4. Use of a substance that inhibits FAAH gene expression in the preparation of a product for reducing the activity of Echinococcus multilocularis, or in reducing the activity of Echinococcus multilocularis; 5. Use of a substance that reduces the content or activity of FAAH in the preparation of a product for reducing the activity of Echinococcus multilocularis, or in reducing the activity of Echinococcus multilocularis.
[0007] 6. Use of a FAAH inhibitor in the preparation of a product for reducing the activity of Echinococcus multilocularis, or in reducing the activity of Echinococcus multilocularis.
[0008] In the above, the FAAH inhibitor may be PF-3845.
[0009] The treatment and / or prevention of alveolar echinococcosis can be embodied in the killing of Echinococcus multilocularis.
[0010] The multilocular Echinococcus tapeworm may be a protoscolecele or a tapeworm stage vesicle (a multilocular Echinococcus tapeworm larva: i.e., an echinococcosis, also known as a tapeworm stage).
[0011] In the present invention, the product may be a medicine.
[0012] Experiments have shown that the fatty acid amide hydrolase inhibitor PF-3845 can destroy the head hook, sucker, microvilli and other structures of the protoscole of Echinococcus multilocularis, causing the protoscole to lyse and die, and can also destroy the structure of the vesicles in the tapeworm stage, causing the vesicles to collapse. This shows that the fatty acid amide hydrolase inhibitor PF-3845 has a good killing effect on Echinococcus multilocularis and can be used as a drug for the preparation of drugs for the treatment of alveolar echinococcosis.
[0013] The present invention is further described in detail below in conjunction with specific embodiments, and the examples provided are only for illustrating the present invention, rather than for limiting the scope of the present invention. The examples provided below can be used as a guide for further improvements by those of ordinary skill in the art, and do not constitute a limitation of the present invention in any way. BRIEF DESCRIPTION OF THE DRAWINGS
[0014] Figure 1 :The effect of different concentrations of FAAH inhibitor PF-3845 on the killing of Echinococcus multilocularis protoscolex (methylene blue staining).
[0015] Figure 2 :Effects of different concentrations of FAAH inhibitor PF-3845 on the survival rate of Echinococcus multilocularis protoscolex.
[0016] Figure 3 :The effects of FAAH inhibitor PF-3845 (20 μM) on the morphological structure of the protoscolecus of Echinococcus multilocularis were observed under optical microscopy.
[0017] Figure 4 :The effects of FAAH inhibitor PF-3845 (20 μM) on the morphological structure of the protoscolecus of Echinococcus multilocularis were observed by scanning electron microscopy.
[0018] Figure 5 :The effects of lipid FAAH inhibitor PF-3845 (20 μM) on the morphological structure of vesicles in the tapeworm stage of Echinococcus multilocularis were observed under optical microscopy.
[0019] Figure 6 :The effects of FAAH inhibitor PF-3845 (20 μM) on the morphological structure of vesicles in the tapeworm stage of Echinococcus multilocularis were observed using scanning electron microscopy. DETAILED DESCRIPTION
[0020] The experimental methods in the following examples are conventional methods unless otherwise specified, and are performed according to the techniques or conditions described in the literature in the art or according to the product instructions. The materials, reagents, instruments, etc. used in the following examples are all commercially available unless otherwise specified. The quantitative tests in the following examples are all repeated at least three times, and the results are averaged.
[0021] PF-3845: Abcam; Catalog Number: AB120894; CAS: 1196109-52-0.
[0022] Example 1: Application of fatty acid amide hydrolase inhibitor PF-3845 as a drug for the treatment of alveolar echinococcosis This example obtains the killing data of fatty acid amide hydrolase inhibitor PF-3845 on the protoscoleces and vesicles of Echinococcus multilocularis cultured in vitro, and finds that fatty acid amide hydrolase inhibitor PF-3845 can be used for the preparation of drugs for treating alveolar echinococcosis. Its application test is as follows: 1. Drug intervention of Echinococcus multilocularis protoscoleces cultured in vitro The protoscoleces (i.e., larval stage) of Echinococcus multilocularis were aseptically isolated in vitro and placed in a 96-well plate containing 200 μL of culture medium (1% penicillin (mass percentage) + 10% fetal bovine serum (volume percentage) + RPMI-1640 culture medium). Then, different concentrations of the fatty acid amide hydrolase inhibitor PF-3845 were added to the culture system for intervention. PF-3845 was first dissolved in DMSO to prepare a 200 mM storage solution. The experiment set up a PF-3845 intervention group (1 μM, 10 μM, 25 μM, 50 μM, that is, the final concentrations of PF-3845 in the culture system were set to 1 μM, 10 μM, 25 μM, 50 μM, respectively) and a solvent control group (final concentration was 0.1% DMSO control group, that is, DMSO of the same volume as the intervention group was added to the culture system, and the final concentration was 0.1%). The worms were collected 3 days, 6 days, 9 days, and 12 days after the intervention, and the activity of the protoscolex was detected by methylene blue staining. Scanning electron microscopy was used to observe the changes in the morphological structure of the worms 12 days after the intervention.
[0023] The experimental results are shown in Figure 1 and Figure 2 After 12 days of intervention, the protoscolex activity of the 0.1% DMSO control group was 93 ± 0.7%, and the protoscolex activity of the PF-3845 intervention groups at 1 μM, 10 μM, 25 μM, and 50 μM decreased to 93 ± 3.1%, 43 ± 8.5%, 3 ± 1.0%, and 2 ± 1.4%, respectively. The protoscolex activity of PF-3845 at concentrations of 25 μM and 50 μM was significantly lower than that of the 0.1% DMSO control group.
[0024] Following the same drug intervention method as above, the final concentration of PF-3845 was set to 20 μM. The results showed that after 12 days of intervention with the inhibitor PF-3845 at a concentration of 20 μM, optical microscopy revealed that the activity of the protoscolecere was reduced, the body was atrophied, and the head hook fell off ( Figure 3 Scanning electron microscopy revealed that the protoscolex was atrophied, the head hook had fallen off, the sucker was destroyed, and the microvilli were truncated ( Figure 4 ). This indicates that the fatty acid amide hydrolase inhibitor PF-3845 has a good killing effect on the protoscoleces of Echinococcus multilocularis cultured in vitro.
[0025] 2. Drug intervention of in vitro cultured tapeworm vesicles of Echinococcus multilocularis The tapetum-stage vesicles of Echinococcus multilocularis were obtained by aseptic culture in vitro, and the vesicles were placed in a 24-well plate containing 1 mL of culture medium (1% penicillin-streptomycin + 10% fetal bovine serum + RPMI-1640 culture medium). Then, different concentrations of fatty acid amide hydrolase inhibitor PF-3845 were added to the culture system for intervention, and DMSO was used to dissolve and prepare a 200 mM storage solution. The PF-3845 intervention group (20 μM, that is, the final concentration of PF-3845 in the culture system was set to 20 μM) and the solvent control group (final concentration of 0.1% DMSO control group, that is, the same volume of DMSO as the intervention group was added to the culture system, and the final concentration was 0.1% (volume percentage)). The integrity and collapse of the tapetum-stage vesicles were observed by optical microscopy and electron microscopy 12 days after intervention.
[0026] The experimental results are shown in Figure 5 and Figure 6 The fatty acid amide hydrolase inhibitor PF-3845 intervention group treated Echinococcus multilocularis vesicles with 20 μM for 12 days, and the vesicle wall lost its luster and collapsed significantly. This indicates that the fatty acid amide hydrolase inhibitor PF-3845 has a good killing effect on the Echinococcus multilocularis vesicles cultured in vitro.
[0027] In summary, the present invention discloses for the first time that fatty acid amide hydrolase inhibitor PF-3845 and the like are a new type of anti-alveolar echinococcosis drug; pharmacodynamic experimental data show that fatty acid amide hydrolase inhibitor PF-3845 has a killing effect on the protoscolex of Echinococcus multilocularis, and inhibits and destroys the growth of vesicles in the tapeworm stage, indicating that PF-3845 can be used to treat alveolar echinococcosis.
[0028] The present invention has been described in detail above. For those skilled in the art, without departing from the purpose and scope of the present invention, and without the need to carry out unnecessary experimental conditions, the present invention can be implemented in a wide range under equivalent parameters, concentrations and conditions. Although the present invention provides specific embodiments, it should be understood that the present invention can be further improved. In a word, according to the principles of the present invention, the application is intended to include any changes, uses or improvements to the present invention, including departure from the disclosed scope in the application, and changes made with conventional techniques known in the art.
Claims
1. Use of a substance that inhibits FAAH gene expression in the preparation of a product for treating and / or preventing alveolar echinococcosis, or in the treatment of alveolar echinococcosis.
2. Use of substances that reduce the content or activity of FAAH in the preparation of products for treating alveolar echinococcosis, or in the treatment of alveolar echinococcosis.
3. Use of FAAH inhibitors in the preparation of products for treating alveolar echinococcosis, or in the treatment of alveolar echinococcosis.
4. The use according to claim 3, characterized in that: The FAAH inhibitor is PF-3845.
5. The use according to any one of claims 1 to 4, characterized in that: The treatment and / or prevention of alveolar echinococcosis is embodied in the killing of the protoscoleces or vesicles of Echinococcus multilocularis.
6. Use of a substance that inhibits FAAH gene expression in the preparation of a product for reducing the activity of Echinococcus multilocularis, or in reducing the activity of Echinococcus multilocularis.
7. Use of a substance that reduces the content or activity of FAAH in the preparation of a product for reducing the activity of Echinococcus multilocularis, or in reducing the activity of Echinococcus multilocularis.
8. Use of a FAAH inhibitor in the preparation of a product for reducing the activity of Echinococcus multilocularis, or in reducing the activity of Echinococcus multilocularis.
9. The use according to claim 8, characterized in that: The FAAH inhibitor is PF-3845.
Citation Information
Patent Citations
Peripherally restricted FAAH inhibitors
CN103153946A
Novel compounds possessing Anti-echinococcal activity
IN201611004817A
Pharmaceutical compositions and their use in the treatment of parasitoses
US5178857A
